Please assess the completion status of the following clinical trial:

Trial Title: A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Non-squamous cell Non Small Cell Lung Cancer (NSCLC) disease~* Clinical stage IIIB/IV or recurrent disease after surgery~* No prior systemic chemotherapy, immunotherapy, targeted therapy or biological therapy, including adjuvant therapy~* Prior radiation therapy is allowed to less than 25% of the bone marrow~* Measurable disease as defined by response evaluation criteria in solid tumors (RECIST)~* The Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1~* Adequate organ function~* Estimated life expectancy of at least 12 weeks~Exclusion Criteria:~* Clinically significant third-space fluid collections~* Central nervous system disease other than stable and treated brain metastasis~* More than 3 weeks interval between the surgery and enrollment request date~* Unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), for a 5 days period~* Unable or unwilling to take folic acid or vitamin B12 supplementation~* Unable to take corticosteroids.~* Serious concomitant disorder that, in the opinion of the investigator, would compromise the patient's ability to adhere to the protocol~* Currently have and historically had interstitial pneumonitis (interstitial pneumonia) or pulmonary fibrosis manifested as opacity on Chest x-ray or Computed tomography (CT)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemetrexed + Carboplatin (Type: EXPERIMENTAL): After four 21-day cycles of Pemetrexed plus Carboplatin treatment, Pemetrexed monotherapy is continued until study discontinuation.

Based on this trial design, predict the completion outcome and termination type (if applicable).